At the same time, they point out that CD33, and to a less extent also CD25 and FcεRI, are very well-suited BMMC surface markers for targeted antibody therapies, while CD22, CD30, and CD123 are less suited cell surface targets except for CD123 in ASM-AHN cases. This evidence concerns the gene CD33 and aggressive systemic mastocytosis.